BICALUTAMIDE tablet Amerika Serikat - Inggris - NLM (National Library of Medicine)

bicalutamide tablet

remedyrepack inc. - bicalutamide (unii: a0z3nau9dp) (bicalutamide - unii:a0z3nau9dp) - bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (lhrh) analog for the treatment of stage d 2 metastatic carcinoma of the prostate. bicalutamide tablets 150 mg daily is not approved for use alone or with other treatments [see clinical studies (14.2)]. bicalutamide is contraindicated in: - hypersensitivity bicalutamide is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. hypersensitivity reactions including angioneurotic edema and urticaria have been reported. - women bicalutamide has no indication for women, and should not be used in this population. - pregnancy bicalutamide can cause fetal harm when administered to a pregnant woman [see us

Bicalutamide Fair-Med 50mg Film-coated Tablets Malta - Inggris - Medicines Authority

bicalutamide fair-med 50mg film-coated tablets

fair-med healthcare gmbh planckstr. 13, 22765 hamburg, germany - bicalutamide - film-coated tablet - bicalutamide 50 mg - endocrine therapy

PHL-BICALUTAMIDE TABLET Kanada - Inggris - Health Canada

phl-bicalutamide tablet

pharmel inc - bicalutamide - tablet - 50mg - bicalutamide 50mg - antineoplastic agents

NU-BICALUTAMIDE TABLET Kanada - Inggris - Health Canada

nu-bicalutamide tablet

nu-pharm inc - bicalutamide - tablet - 50mg - bicalutamide 50mg - antineoplastic agents

NTP-BICALUTAMIDE TABLET Kanada - Inggris - Health Canada

ntp-bicalutamide tablet

teva canada limited - bicalutamide - tablet - 50mg - bicalutamide 50mg - antineoplastic agents

Bicalutamide 150mg tablets Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

bicalutamide 150mg tablets

alliance healthcare (distribution) ltd - bicalutamide - oral tablet - 150mg